First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate

Ahmet Emre Eskazan; Mesut Ayer; Bulent Kantarcioglu; Deniz Arica; Naciye Demirel; Demet Aydin; Fevzi Firat Yalniz; Tugrul Elverdi; Ayse Salihoglu; Muhlis Cem Ar; Seniz Ongoren Aydin; Zafer Baslar; Yildiz Aydin; Nukhet Tuzuner; Ugur Ozbek; Teoman Soysal

doi:10.1111/bjh.12937

First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate

Ahmet Emre Eskazan, Mesut Ayer, Bulent Kantarcioglu, Deniz Arica, Naciye Demirel, Demet Aydin, Fevzi Firat Yalniz, Tugrul Elverdi, Ayse Salihoglu, Muhlis Cem Ar, Seniz Ongoren Aydin, Zafer Baslar, Yildiz Aydin, Nukhet Tuzuner, Ugur Ozbek, Teoman Soysal

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Original language	English
Pages (from-to)	139-141
Number of pages	3
Journal	British Journal of Haematology
Volume	167
Issue number	1
DOIs	https://doi.org/10.1111/bjh.12937
State	Published - Oct 1 2014

Keywords

Chronic myeloid leukaemia
Efficacy
Generic
Imatinib mesylate

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.12937

Cite this

Eskazan, A. E., Ayer, M., Kantarcioglu, B., Arica, D., Demirel, N., Aydin, D., Yalniz, F. F., Elverdi, T., Salihoglu, A., Ar, M. C., Ongoren Aydin, S., Baslar, Z., Aydin, Y., Tuzuner, N., Ozbek, U., & Soysal, T. (2014). First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate. British Journal of Haematology, 167(1), 139-141. https://doi.org/10.1111/bjh.12937

@article{9955baad678a499fb8af357f78b8c678,

title = "First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate",

keywords = "Chronic myeloid leukaemia, Efficacy, Generic, Imatinib mesylate",

author = "Eskazan, \{Ahmet Emre\} and Mesut Ayer and Bulent Kantarcioglu and Deniz Arica and Naciye Demirel and Demet Aydin and Yalniz, \{Fevzi Firat\} and Tugrul Elverdi and Ayse Salihoglu and Ar, \{Muhlis Cem\} and \{Ongoren Aydin\}, Seniz and Zafer Baslar and Yildiz Aydin and Nukhet Tuzuner and Ugur Ozbek and Teoman Soysal",

year = "2014",

month = oct,

day = "1",

doi = "10.1111/bjh.12937",

language = "English",

volume = "167",

pages = "139--141",

number = "1",

}

Eskazan, AE, Ayer, M, Kantarcioglu, B, Arica, D, Demirel, N, Aydin, D, Yalniz, FF, Elverdi, T, Salihoglu, A, Ar, MC, Ongoren Aydin, S, Baslar, Z, Aydin, Y, Tuzuner, N, Ozbek, U & Soysal, T 2014, 'First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate', British Journal of Haematology, vol. 167, no. 1, pp. 139-141. https://doi.org/10.1111/bjh.12937

TY - JOUR

T1 - First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate

AU - Eskazan, Ahmet Emre

AU - Ayer, Mesut

AU - Kantarcioglu, Bulent

AU - Arica, Deniz

AU - Demirel, Naciye

AU - Aydin, Demet

AU - Yalniz, Fevzi Firat

AU - Elverdi, Tugrul

AU - Salihoglu, Ayse

AU - Ar, Muhlis Cem

AU - Ongoren Aydin, Seniz

AU - Baslar, Zafer

AU - Aydin, Yildiz

AU - Tuzuner, Nukhet

AU - Ozbek, Ugur

AU - Soysal, Teoman

PY - 2014/10/1

Y1 - 2014/10/1

KW - Chronic myeloid leukaemia

KW - Efficacy

KW - Generic

KW - Imatinib mesylate

UR - http://www.scopus.com/inward/record.url?scp=84908876492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908876492&partnerID=8YFLogxK

U2 - 10.1111/bjh.12937

DO - 10.1111/bjh.12937

M3 - Article

C2 - 24815307

AN - SCOPUS:84908876492

SN - 0007-1048

VL - 167

SP - 139

EP - 141

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 1

ER -

First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this